---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-25-000084"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T21:14:37.628349+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics Q2 revenue $213.1M (+1% YoY); raises FY2025 revenue guidance

## Summary
- GAAP net loss $330.5M ($3.57/share) includes $316.7M impairment; adjusted EPS $0.05.
- Hereditary cancer testing revenue +9% YoY in Oncology; MyRisk with RiskScore volume +14%.
- Raised 2025 revenue guidance to $818-828M from $807-823M; adjusted EPS reiterated at $(0.02)-$0.02.
- New $200M credit facility with OrbiMed entered July 31; plans to launch ultra-sensitive MRD test H1 2026.
- GeneSight revenue down 12% due to UHC coverage discontinuation; prenatal revenue +7%.

## SEC filing metadata
- accession: 0000899923-25-000084
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992325000084/0000899923-25-000084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992325000084/mygn-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-25-000084
- JSON: https://secwatch.observer/filing/0000899923-25-000084.json
- Plain text: https://secwatch.observer/filing/0000899923-25-000084.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.